MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 157 filers reported holding MERSANA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,865 | -58.4% | 3,043 | +7.8% | 0.00% | – |
| Q2 2023 | $9,284 | +309366.7% | 2,822 | +362.6% | 0.00% | – |
| Q1 2023 | $3 | -25.0% | 610 | 0.0% | 0.00% | – |
| Q4 2022 | $4 | -99.9% | 610 | -11.8% | 0.00% | – |
| Q3 2022 | $5,000 | +66.7% | 692 | +13.4% | 0.00% | – |
| Q2 2022 | $3,000 | -98.5% | 610 | -98.7% | 0.00% | -100.0% |
| Q1 2022 | $194,000 | +6366.7% | 48,710 | +7885.2% | 0.00% | – |
| Q4 2021 | $3,000 | -50.0% | 610 | 0.0% | 0.00% | – |
| Q3 2021 | $6,000 | -88.0% | 610 | -83.3% | 0.00% | – |
| Q2 2021 | $50,000 | -67.5% | 3,660 | -61.5% | 0.00% | -100.0% |
| Q1 2021 | $154,000 | -78.2% | 9,510 | -64.3% | 0.00% | -80.0% |
| Q4 2020 | $708,000 | +420.6% | 26,610 | +264.0% | 0.01% | +400.0% |
| Q3 2020 | $136,000 | -20.5% | 7,310 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $171,000 | – | 7,310 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |